Sponsor Pipeline

Nuvectis Pharma, Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
2
Active Trials
2
Recruiting
4
Disease Areas
4
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-07 NCT05226507
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in…		 critical Trial terminated
2026-08-07 NCT05226507
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in…		 critical Trial terminated: Study terminated due to various reasons impacting the feasibility of future clinical development
2026-08-07 NCT05226507
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in…		 date change Primary completion moved earlier: 2025-12 -> 2025-01-01
2026-08-07 NCT05226507
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in…		 date change Completion moved earlier: 2025-12 -> 2025-01-01
Active Trials by Phase
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 1
NCT05873686 A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers Advanced Solid Tumor Recruiting
NCT07315113 Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell… EGFR Mutation Positive Non-small Cell Lung Cancer Recruiting
Disease Areas
Non-Small Cell Lung Cancer (NSCLC) (2) Lung Cancer (2) Kidney Cancer (1) Mesothelioma (1)
Get alerts when Nuvectis Pharma, Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free